An Open label, Single arm, clinical Study to evaluate efficacy of Kapiva Dia Free Juice as an adjuvant therapy for Type 2 Diabetic Patients and Improving QO

Kapiva Adret Retail Pvt Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Subjects aged > 18 years of age who agree to participate in the study willing and able to answer the questionnaire and give their written informed consent.
•2. Participant with initial HBA1c value 6.5% and above
•3. Subjects with a physician certified report on their sugar profile of 3 months
•prior to enrolment for trial.
•4. Patients with a diagnosis of T2DM for >1 year prior to signing up for clinical
•5. Patients who are under the treatment of oral antidiabetic drugs
•6. Patients who have not changed their medication in the last three months prior
•to signing up for the study. (However, dosage modifications are allowed)
•7. Subjects with Body Mass Index (BMI) >27 kg/m2 and <45 kg/m2
•8. Women of childbearing potential must be willing to use double-barrier contraception for the entire study

•1.Pregnant and lactating women
•2. Patients who are on insulin therapy.
•3. Patients with a history of chronic illness type 1 diabetes and /or history of
•ketoacidosis
•4. Patients with Insulin use and/or hyperosmolar hyperglycaemic state
•5. Patients with secondary diabetes (including disease of the exocrine pancreas,
•endocrinopathies)
•6. Any condition of the patient which may have an impact on the objective and
•outcome of the trial example: patients currently undergoing major/ minor surgical procedures

发起方

Kapiva Adret Retail Pvt Ltd